Galectin NAVIGATE trial: belapectin reduces varices by 48.9% in per-protocol but misses ITT primary endpoint

GALECTIN THERAPEUTICS INC

In ITT (N=355), primary composite endpoint not statistically significant; varices incidence reduced 43.2% with 2mg/kg vs placebo.
In per-protocol (n=290), belapectin 2mg/kg showed 48.9% reduction in varices (p<0.05).
Safety profile favorable; adverse events comparable across cohorts, no drug-related SAEs.
Additional 36-month data from ~50 patients expected in Q1 2025.
Company will engage with potential partners to determine next steps.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.